What Researchers Did
This study describes the case of a 30-year-old man who developed severe muscle breakdown, lactic acidosis, and multiple organ failure after taking the hepatitis B medication telbivudine.
What They Found
The patient, who had taken 600 mg of telbivudine daily for over 11 months, experienced severe symptoms including weakness, chest tightness, and low blood pressure. Blood tests showed significantly high levels of liver enzymes (ALT 955 U/L, AST 1375 U/L), kidney markers (BUN 14.9 mmol/L), muscle damage (creatine kinase peaked at 8050 U/L), and lactic acid (>20.0 mmol/L). His condition improved with continuous renal replacement therapy and steroids, and his muscle strength returned to normal after more than two months of hyperbaric oxygen therapy, physical therapy, and rehabilitation.
What This Means for Canadian Patients
Canadian patients taking telbivudine for hepatitis B should be aware of potential severe side effects like muscle breakdown and lactic acidosis, which can lead to organ failure. While continuous renal replacement therapy and steroids are crucial for acute stabilization, this case suggests that hyperbaric oxygen therapy, alongside physical therapy and rehabilitation, might support muscle strength recovery after the initial crisis.
Canadian Relevance
No direct Canadian connection identified. The study authors are not Canadian, and the patient was Chinese. The conditions discussed (rhabdomyolysis, lactic acidosis, multiple organ failure) are not Health Canada-recognized indications for HBOT.
Study Limitations
As a single case report, this study's findings cannot be broadly applied to all patients.